352 related articles for article (PubMed ID: 33244099)
1. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
[TBL] [Abstract][Full Text] [Related]
2. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.
Richards JS; Fan HY; Liu Z; Tsoi M; Laguë MN; Boyer A; Boerboom D
Oncogene; 2012 Mar; 31(12):1504-20. PubMed ID: 21860425
[TBL] [Abstract][Full Text] [Related]
3. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.
Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS
Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546
[TBL] [Abstract][Full Text] [Related]
4. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
5. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium.
Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K
J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144
[TBL] [Abstract][Full Text] [Related]
6. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
7. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
8. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
9. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
10. Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.
Dalin MG; Zou Z; Scharin-Täng M; Safari R; Karlsson C; Bergo MO
Cardiovasc Res; 2014 Feb; 101(2):229-35. PubMed ID: 24259500
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.
Laguë MN; Paquet M; Fan HY; Kaartinen MJ; Chu S; Jamin SP; Behringer RR; Fuller PJ; Mitchell A; Doré M; Huneault LM; Richards JS; Boerboom D
Carcinogenesis; 2008 Nov; 29(11):2062-72. PubMed ID: 18687666
[TBL] [Abstract][Full Text] [Related]
12. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Wang X; Praça MSL; Wendel JRH; Emerson RE; DeMayo FJ; Lydon JP; Hawkins SM
Am J Pathol; 2021 Jul; 191(7):1281-1291. PubMed ID: 33882289
[TBL] [Abstract][Full Text] [Related]
13. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F; Milner-White EJ; Going JJ; Birnie GD
J Pathol; 1999 Mar; 187(4):433-8. PubMed ID: 10398103
[TBL] [Abstract][Full Text] [Related]
14. MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.
Tirodkar TS; Budiu RA; Elishaev E; Zhang L; Mony JT; Brozick J; Edwards RP; Vlad AM
PLoS One; 2014; 9(7):e102409. PubMed ID: 25078979
[TBL] [Abstract][Full Text] [Related]
15. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
16. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.
Figueiredo ML; Stein TJ; Jochem A; Sandgren EP
Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894
[TBL] [Abstract][Full Text] [Related]
17. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
[TBL] [Abstract][Full Text] [Related]
18. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
[TBL] [Abstract][Full Text] [Related]
20. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
